Video Preview
🎧 Part I Podcast free on Apple Podcasts and Spotify.
🎧 Part II Podcast episode for paid subscribers only. Also available on Apple Podcasts and Spotify.
To listen to paid episodes in Apple or Spotify, link your Substack subscription via the show settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).
Table of Contents
What the bill actually says, and what it carefully avoids saying
The friendly PC, explained without the euphemisms
The accounting already confessed years ago
Oregon is the test kitchen and 2029 is the oven timer
Enforcement design is the whole ballgame
The 82 percent number is doing a lot of work
Who actually eats this
What happens to the debt stack
The market already voted, months before the bill dropped
What compliance looks like if this ever becomes law
The records and data wrinkle nobody is pricing
Odds, timelines, and the three things worth watching
Abstract
The Stop Corporate Takeovers of Physicians Act, introduced September 16, 2026 by Warren, Wyden, Merkley, Hoyle, Ocasio-Cortez, and Subramanyam, would create a federal ban on the corporate practice of medicine, modeled on Oregon SB 951. Key facts and figures for orientation:
82 percent of US physicians employed by hospitals or corporate entities as of January 2026, up from 62 percent in 2019. Corporate and hospital entities own 63.9 percent of practices.
Enforcement runs through three channels: FTC, state attorneys general, and a private right of action for physicians with treble damages.
Physician practice management deal count: 851 in 2021, 105 in the first half of 2026. Q2 2026 came in at 71 deals versus 89 in Q1 and 102 in Q4 2025.
Healthcare services PE deal count down 18.5 percent year over year in Q2 2026, exit count pacing down 26.5 percent, and the installed base of PE-backed healthcare services companies flat for the first year on record.
Oregon SB 951 compliance dates: restrictive covenants immediate as of June 9, 2025, new MSO arrangements January 1, 2026, pre-existing arrangements January 1, 2029.
California SB 351 and AB 1415 both effective January 1, 2026, with a 90-day pre-close notice to the Office of Health Care Affordability.
Core argument: the bill is aimed at private equity in the press release, but the operative language targets any non-licensee exercising ownership powers over a medical practice, which describes payer-owned and retail-owned physician platforms at least as well as it describes a dermatology roll-up in Ohio. The mechanism that would actually change behavior is not the ownership ban, which is easy to paper around, but the combination of a fixed-fee management services requirement, a ban on stock transfer restriction agreements, and treble damages available to any disgruntled physician with a laptop.
What the bill actually says, and what it carefully avoids saying
The headline version is simple enough that it fits in a tweet, which is exactly where most people encountered it. Ban corporate takeovers of your doctor’s office. Get Wall Street out of the exam room. Fine. The operative text is more interesting than the press release, and the gap between the two is where all the fun lives.
The bill would make it unlawful for private equity funds, insurance companies, and other for-profit corporations to own or control a medical practice. That word “control” is doing heroic work, because ownership was never the actual mechanism. Almost nobody in the modern era buys the professional corporation outright. The bill’s drafters know this, which is why the second prong goes after management services organizations directly, prohibiting an MSO from controlling a practice through a friendly or captive physician arrangement. It requires that physician owners be meaningfully engaged in the practice of medicine in the state where the practice operates, which is a direct shot at the nominee shareholder who owns 47 professional corporations across 31 states and has not personally seen a patient since the Obama administration. It prohibits corporate interference with clinical decisions. And it voids noncompetes and nondisclosure agreements between management companies and clinicians, which sounds like a labor provision and is actually an enforcement provision, for reasons that become obvious in section five.
What the bill does not do is also worth cataloging, because a lot of commentary got this wrong in the first 48 hours. It does not unwind hospital employment of physicians. Nonprofit health systems have statutory or judicial exceptions to corporate practice doctrine in most states, and the federal bill as described targets for-profit corporate ownership and investor control rather than tax-exempt system employment. That matters enormously, because hospitals and health systems are the single largest bucket inside that 82 percent corporate employment figure. It does not touch payer ownership of anything other than practices, so pharmacy benefit management, specialty pharmacy, home health assessments, and the rest of the vertically integrated payer stack stay where they are. It does not address the thing that drove physicians into corporate arms in the first place, which is a Medicare physician fee schedule conversion factor that has lost roughly a third of its purchasing power since 2001 while practice costs went in the other direction. And it does not, as far as anyone can tell from the summaries, create a workable definition of “control” that distinguishes a management company that handles credentialing and payroll from one that sets panel size and orders the ultrasound machines. Oregon tried to enumerate that list. It took a lot of words and still leaves room.
There is also no Republican co-sponsor. This is a messaging bill in the technical sense, which does not mean it is unimportant. Messaging bills are how state legislatures get their homework.
The friendly PC, explained without the euphemisms
For anyone who has never sat through a diligence call on one of these, the structure works like this and it is dumber than you think.
State corporate practice doctrine, which exists in some form in a majority of states and traces back to the 1930s and 1940s in most of them, says a corporation cannot practice medicine and cannot employ a physician to do so. Oregon’s version dates to 1947. So the sponsor does not buy the practice. The sponsor buys or forms a management services organization, a normal LLC or corporation that can be owned by anyone, including a fund in Delaware, a fund of funds in Luxembourg, and a pension in Ontario. The medical practice itself stays in a professional corporation owned by a licensed physician. That physician is sometimes a real practicing doctor in the group, sometimes the group’s founder, and sometimes a single friendly physician who holds the shares of many professional corporations across many states for a modest annual fee and a hold-harmless agreement.
The PC and the MSO then sign two documents that do all the work. The first is a management services agreement, which delegates everything non-clinical to the MSO: billing, coding, collections, payer contracting, scheduling, staffing, supply purchasing, compliance, marketing, human resources, information technology, legal, real estate. The management fee is usually structured as a percentage of net revenue, or a cost-plus arrangement, or in the more aggressive versions, a residual that is defined as whatever is left after physician compensation. The second is a stock transfer restriction agreement, sometimes called a continuity agreement or a succession agreement, under which the friendly physician agrees that the MSO can compel the transfer of the PC’s shares to another physician designated by the MSO, at a nominal price, at the MSO’s discretion, for reasons that can include simply being asked.
Take those two documents together and you have functional ownership. The MSO controls who owns the PC, controls the economics of the PC, and controls every operational lever short of the actual clinical decision. The physician shareholder is a hat rack. This is not a fringe structure or a gray-area workaround used by cowboys. It is the standard structure. It is in the S-1s. It is in the credit agreements. It is what every healthcare lawyer at every large firm builds for every client, and it has been blessed by enough state regulators through enough periods of inattention that the industry stopped thinking of it as a workaround at all.
The California attorney general filed an amicus brief in 2026 attacking exactly this pairing, the stock transfer restriction plus the MSA termination right, as the thing that converts a nominal physician ownership into a de facto corporate one. That brief is the shape of the coming fight, and it is a much more serious document than the federal bill, because it does not need Congress.
The accounting already confessed years ago
Here is the part that healthcare lawyers handle gingerly and CFOs handle not at all, because it has been sitting in plain sight for two decades.
Under ASC 810, an entity consolidates a variable interest entity when it has the power to direct the activities that most significantly impact the VIE’s economic performance and the obligation to absorb losses or the right to receive benefits that could be significant. Every PE-backed and public physician platform consolidates its friendly professional corporations as VIEs. They have to. The auditors require it. If the MSO did not have power over the PC’s significant activities and did not absorb its residual economics, the PC would not consolidate, and the platform’s revenue would collapse to a management fee line rather than the gross professional revenue that investors underwrite.
So the structure’s own financial statements assert, under penalty of Sarbanes-Oxley for the public ones, that the management company has power over and absorbs the residual returns of the medical practice. Then the same companies’ legal opinions assert that the management company does not own or control the medical practice. Both statements cannot be true in any ordinary-language sense. They survive together because they answer different questions posed by different regulators who historically did not read each other’s mail.
A federal corporate practice ban with a private right of action changes that. Plaintiffs’ counsel will not need discovery to establish control. They will need a 10-K and a highlighter. The VIE footnote, the related-party disclosure, the risk factor that says “our business would be materially harmed if state regulators determined that our arrangements with the professional corporations violate corporate practice of medicine laws,” which appears verbatim in dozens of filings, is a confession drafted by the defendant’s own counsel and filed with the SEC. That risk factor was always a hedge against a theoretical enforcement action. Under this bill it becomes Exhibit A.
Oregon is the test kitchen and 2029 is the oven timer
The federal bill is modeled on Oregon SB 951, signed June 9, 2025, and amended by HB 3410, so the Oregon experience is the closest thing to a forecast anyone has.
Oregon does three things that matter. It prohibits an MSO and its shareholders, directors, officers, employees, and contractors from owning or controlling a majority interest in a professional medical entity that the MSO manages, which kills dual ownership outright. It bars the same people from serving simultaneously as director, officer, employee, or contractor of both the MSO and the practice, which kills the classic arrangement where the platform’s chief medical officer is also the PC’s sole shareholder and sole board member. And it sharply limits stock transfer restriction agreements, which kills the leash.
It also enumerates the operational controls an MSO cannot exercise, and the list is specific in a way that should make platform operators sweat: scheduling, compensation of clinical staff, coding, billing, payer contracting terms, clinical staffing decisions, and equipment selection. Anyone who has built a PPM knows that roughly 80 percent of the synergy case in an LBO model lives inside that list. Payer contracting alone is usually the single largest value driver in a roll-up, because the whole thesis is that a 400-physician platform negotiates rates a 6-physician group cannot. If the MSO cannot set payer contracting terms, the rate lift thesis needs a new home.
The implementation calendar is where the real information is. Restrictive covenant provisions took effect immediately on signing. The MSO ownership and control restrictions applied January 1, 2026 to entities formed on or after June 9, 2025 and to ownership transfers after that date. Pre-existing arrangements under continuous ownership get until January 1, 2029. So Oregon effectively froze new structures immediately and gave the installed base a three and a half year runway to either restructure, sell to a compliant buyer, or leave. Nobody knows yet which of those three dominates, because the interesting date has not arrived. Watch 2028, when the sell-side pipeline for Oregon assets either materializes or does not.
Two carve-outs in the Oregon law deserve more attention than they have gotten. Coordinated care organizations under the state’s Medicaid program that existed before January 1, 2026 are exempt. And telemedicine entities with no physical location in Oregon where patients receive services are exempt. That second one is a canyon, not a loophole. If the compliance answer to a corporate practice ban is “operate virtually and do not lease clinical real estate in the state,” then the entire direct-to-consumer telehealth sector, which is built on exactly the friendly PC model in all 50 states, walks through untouched, while the bricks-and-mortar primary care group that employs people in the community eats the full compliance cost. That is an odd set of incentives to create on purpose. The federal bill may or may not replicate it. If it does, expect a very sudden enthusiasm for asynchronous care among people who previously thought it was beneath them.
Enforcement design is the whole ballgame
The substantive prohibition is the boring half. The enforcement architecture is the half that would actually change behavior, and it is built by people who learned from watching antitrust enforcement fail in this exact sector.
Three channels. The Federal Trade Commission gets authority. State attorneys general get the right to sue. And physicians get a private right of action with treble damages.
Channel one is the weakest. The FTC’s recent history against a PE-backed physician platform is not encouraging for anyone hoping the agency solves this. In the US Anesthesia Partners matter, the agency sued both the platform and its sponsor on a roll-up theory, and the court let the sponsor out of the case in 2024 before the platform eventually resolved with the agency. The lesson the industry took from that was that reaching the fund is hard, and the lesson the drafters took was that you cannot rely on a single federal agency with a rotating chair and a finite budget to police thousands of MSAs.
Channel two, state AGs, is more interesting because state AGs have already shown up. California’s attorney general did not wait for Congress before filing the amicus brief on stock transfer restrictions and before settling with a dental management company for two million dollars in penalties, three hundred thousand in restitution, and a 36-month compliance monitor. A monitor is the part that hurts. Penalties get accrued. Monitors sit in your operating meetings.
Channel three is the one that would restructure the market. A private right of action with treble damages, held by every physician who has ever signed a management services agreement, creates a plaintiff’s bar overnight. This is the False Claims Act qui tam dynamic transposed onto contract law. It means enforcement no longer depends on regulatory capacity, political appetite, or election cycles. It depends on whether any one of the 90,000 physicians inside a given platform gets angry about a compensation model change, calls a lawyer, and gets told that the MSA itself is the violation and the damages are three times the management fees collected. And remember that the same bill voids the nondisclosure and non-disparagement clauses that currently keep those physicians quiet, and voids the noncompetes that currently make leaving expensive. The labor provisions are not a separate policy goal bolted on for progressive flavor. They are the ammunition supply for the private right of action. Strip the gag, strip the exit penalty, add treble damages, and you have manufactured a very large number of plaintiffs with nothing to lose.
For anyone modeling this: the exposure is not a fine. It is three times the management fee stream, times the number of professional corporations, times the statute of limitations, defended in parallel across multiple jurisdictions, against a class of plaintiffs whose testimony about who controlled scheduling is going to be unhelpful. Insurance will not cover the bulk of that. Reps and warranties policies certainly will not.
The 82 percent number is doing a lot of work
Every press release around this bill leads with the statistic that more than 82 percent of US physicians were employed by hospitals or corporate entities as of January 2026, up from 62 percent in 2019, with hospitals and corporate entities owning 63.9 percent of practices. The numbers come from the Physicians Advocacy Institute and Avalere and they are real. The framing is where things get slippery.
That 82 percent is dominated by hospital and health system employment, not by private equity. The PE-owned share of US physicians is generally estimated in the high single digits overall, concentrated heavily in a handful of specialties where the economics work: anesthesia, emergency medicine, radiology, dermatology, ophthalmology, gastroenterology, orthopedics, dental, urgent care, and behavioral health. In a few of those, PE-backed platforms have genuinely large local shares, and that concentration is where the credible harm evidence sits. The broad statistic, though, describes a consolidation wave that hospitals ran, and a federal corporate practice ban targeting for-profit and investor ownership would leave most of it exactly where it is.
The harm evidence, for a technical audience, is better than the skeptics admit and narrower than the advocates claim. The strongest findings are on price. Work published in JAMA and JAMA Internal Medicine found roughly 11 percent price increases following PE acquisition of physician practices, with anesthesia specifically showing increases in the mid-twenties percent range after acquisition, driven substantially by out-of-network leverage in the pre-No Surprises Act era. On quality, the most cited result is the hospital study showing hospital-acquired conditions rising about 25 percent after private equity acquisition, with falls up around 27 percent and central line infections up sharply, against a control group, despite the acquired hospitals treating a somewhat lower-risk patient mix afterward. The nursing home literature found roughly a 10 percent relative increase in short-stay mortality. The BMJ systematic review of the whole body of work concluded that the evidence points toward higher costs with no consistent quality improvement, which is a polite way of saying the null hypothesis did not survive.
The honest caveat is that a lot of this is identification-challenged. Acquisition targets are selected, not randomly assigned. Some of the price effect is the intended effect of scale bargaining, which the same policy community celebrates when a physician union does it. And the No Surprises Act already removed the single most extractive mechanism, surprise out-of-network billing, from the playbook in 2022. Several of the most damning findings describe a business model that regulators already killed. Arguing about 2018 anesthesia pricing in 2026 is a bit like passing a law about Blockbuster late fees.
Who actually eats this
Read the operative language rather than the press release and ask who is running a friendly professional corporation structure at scale in the United States today.
The answer, in order of magnitude, starts with a payer. Optum’s physician platform sits around 136,000 employed and affiliated physicians and advanced practice clinicians, making it by a wide margin the largest physician organization in the country, and it is assembled from the same professional corporation and management services architecture as every dermatology roll-up, just with better lawyers and a much larger balance sheet behind it. The bill explicitly names insurance companies. If a federal corporate practice ban passed and were enforced as written, the entity with the largest absolute exposure in the country would be an insurer, not a fund. Next you have the retail and technology entrants, One Medical inside Amazon, Oak Street inside CVS, and the entire direct-to-consumer prescribing sector, all of which run affiliated professional corporations in all 50 states because there is no other lawful way to do it. Then you have the publicly traded physician platforms. Then, well down the list by physician count, you have mid-market sponsor-owned specialty roll-ups, which is the group the bill is named after.
So the accurate description is that this is an anti-vertical-integration bill wearing a private equity costume. That is not a criticism of the policy. There is a coherent argument that payer ownership of physicians raises harder conflict-of-interest questions than fund ownership does, because the payer has a direct financial interest in the utilization decision in a way a generic financial sponsor does not. It is simply a different bill than the one being marketed, and the constituencies that would mobilize against it are considerably larger and better funded than the American Investment Council.
There is also a second-order effect that the bill’s supporters should think about for longer than they have. If independent physicians cannot sell to a management company, and the administrative cost of independence keeps rising, the remaining buyer is the nonprofit hospital system, which is exempt. Hospital acquisition of physician practices produces the largest and best-documented price increases in the entire literature, because the same service moves from a physician office billing to a hospital outpatient department billing a facility fee on top of the professional fee. Site-neutral payment reform has been recommended by MedPAC for years and has gone nowhere. Pass a corporate practice ban without site-neutral payment and the likely result is faster consolidation into the highest-cost setting, with better press. That is the structural irony worth sitting with.
What happens to the debt stack
Credit people should care about this more than deal people, and mostly they do not yet.
In a standard PPM financing, the borrower is the MSO or a holding company above it. The collateral package is MSO equity, MSO assets, and critically, the management services agreement and the receivables it generates. Lenders do not take a security interest in the professional corporation, because they cannot own it either. The entire credit is a bet that the MSA keeps producing cash.
Now void the MSA, or force its restructuring into a fixed fair-market-value fee, and the cash flow the loan was underwritten against changes character completely. A residual-sweep MSA captures practice profit. A fixed-fee MSA captures the cost of services plus a market margin, and leaves the residual with the physicians, which is precisely the point of the reform. The difference between those two, across a levered platform running at five or six turns, is the difference between a performing credit and a restructuring.
Healthcare services is one of the largest sector exposures in US private credit, and the recent history was already unpleasant before any of this. Envision in 2023. Radiology Partners running a liability management exercise. Steward Health Care collapsing in 2024 with landlord and state entanglements that produced actual hospital closures and became the political fuel for half the state bills now pending. Prospect Medical Holdings filing in January 2025. Those were not caused by corporate practice enforcement, they were caused by leverage colliding with reimbursement and labor cost, but they built the political record that makes this bill possible, and they also mean the sector enters any legal shock with thinner covenant cushion than usual.
The practical near-term consequence is in diligence and documentation rather than in defaults. Expect corporate practice compliance representations to get their own section in credit agreements. Expect change-of-law provisions that specifically name state and federal corporate practice statutes. Expect a lot of quiet conversations about whether the 2029 Oregon date is a maturity problem for anything financed in 2026 with a five-year tenor. And expect purchase price allocations to start distinguishing between the portion of EBITDA that comes from genuine administrative scale, which survives any version of this law, and the portion that comes from controlling payer contracting and coding, which does not.
The market already voted, months before the bill dropped
This is the part most of the coverage buried, and it is the part that matters for anyone deploying capital.
Physician practice management deal count peaked at 851 in 2021. The first half of 2026 produced 105. Quarterly, the trajectory is 102 in the fourth quarter of 2025, 89 in the first quarter of 2026, 71 in the second. PitchBook has the segment pacing to finish 2026 down roughly 46 percent against 2025. Healthcare services private equity deal count overall fell 18.5 percent year over year in the second quarter, exit count is pacing down 26.5 percent, and the projected full-year count would be the lowest since 2017.
The most important single datapoint is subtler. The total count of PE-backed healthcare services companies is running flat against 2025, which would be the first year on record with no growth in the installed base. For a strategy whose whole identity is compounding platform count and then compounding practice count inside each platform, an installed base that stops growing is not a slow year. It is a regime change.
Value held up better than count, falling only about 7.3 percent in the first half, because a handful of very large transactions carried the period. That is the standard late-cycle signature: fewer, larger, safer. Capital concentrating into assets with defensible cash flows and clean regulatory stories, while the small tuck-in that used to be the engine of the roll-up thesis becomes uneconomic once every deal needs a 90-day state notice filing, a corporate practice opinion, and a structure that might need rebuilding in three years.
Multiples moved accordingly. Median enterprise value to EBITDA across public healthcare services comparables came down to roughly 11.5 times in 2025 from about 14.5 times the year prior. Well-run specialty groups with diversified payer mix still clear double digits. Everything else is negotiating.
How much of this is regulation and how much is macro is genuinely unresolved, and anyone telling you they know the split is selling something. Interest rates, a soft utilization environment, a constipated exit market, and eight-plus years of accumulated portfolio inventory would have produced a slowdown with or without Oregon. What the regulation clearly did was raise the cost and duration of every transaction, which hits small deals disproportionately, which is why the segment built on small deals is down the most.
What compliance looks like if this ever becomes law
Assume for the sake of argument that something resembling this passes, federally or in enough large states to be effectively national. What does a compliant platform look like in 2030.
The management services agreement becomes a fixed fee or a cost-plus fee set at fair market value, documented by a third-party valuation, renewed periodically, with no residual sweep and no percentage-of-collections structure. The stock transfer restriction agreement disappears, or survives only in a form tied to actual physician events like death, disability, retirement, or loss of license, with fair value payment rather than nominal price. The professional corporation gets a real board with real physician directors who have real fiduciary duties and, importantly, are not simultaneously employed by the management company. Physician owners actually practice, in the actual state. Payer contracting authority moves back to the practice, with the MSO in an advisory and administrative role that has to be documented as advisory rather than directive. Clinical staffing, scheduling, coding, and equipment decisions get formal physician sign-off with an audit trail, because the audit trail is now the defense exhibit.
And the economics change. If the residual stays with physicians, the value the sponsor captures is limited to genuine administrative efficiency: revenue cycle at scale, purchasing, technology, compliance, real estate, and capital access. That is a real business. It is a services business with services business margins, not a levered equity business with equity returns. It supports a different multiple, a different capital structure, and a different holding period.
Which is exactly what the policy intends. The reform is not really about who holds the shares. It is about who gets the residual. Everything else is plumbing.
The cynical compliance response is already visible in Oregon and California, and it is governance theater: independent-looking boards staffed by physicians who are economically dependent on the platform anyway, MSAs with fixed fees set at a fair market value that happens to equal the previous residual, and clinical authority memorialized in a policy nobody reads. That works until the first physician plaintiff’s deposition, at which point the question is not what the policy said but who actually decided the panel size. Under a treble damages regime with no NDA to hide behind, that question gets asked a lot.
The records and data wrinkle nobody is pricing
One angle that has gone almost entirely unmentioned, and that anyone working in health data should be thinking about hard.
Under HIPAA, the covered entity is the provider. In an MSO-PC structure, the professional corporation is the covered entity and the legal custodian of the designated record set. The management company is a business associate operating under a business associate agreement. That distinction has been largely theoretical in practice, because the same people ran both sides and the record lived in an EHR the MSO paid for, on infrastructure the MSO controlled, administered by MSO employees.
Break the control link and the distinction stops being theoretical. Custody of the medical record, the right to respond to a release of information request, the revenue associated with fulfilling those requests, the authority to sign a data use agreement, the decision to join a health information exchange or a TEFCA qualified network, the obligation not to engage in information blocking, and the ability to license de-identified data all attach to the covered entity, which is the practice, not the management company. Several platforms have built real revenue lines on the assumption that they control the data their affiliated practices generate. If the physician-owned entity is the one with the actual legal authority, and if that entity now has independent governance and an unmuzzled right to sue, those assumptions need revisiting. Contracts that assign data rights from a captive PC to its own management company are exactly the kind of related-party arrangement that a fair market value and arm’s length standard scrutinizes first.
There is also a mundane operational version of this problem. Information blocking obligations attach to healthcare providers, health IT developers, and health information networks. A management company that controls the EHR configuration and the release workflow while insisting it does not control the practice is making an argument that will be tested from two directions at once. Pick a lane.
Odds, timelines, and the three things worth watching
Probability the Stop Corporate Takeovers of Physicians Act becomes law in this Congress: close enough to zero that pricing it into a model would be malpractice. No Republican co-sponsor, no committee markup scheduled, an industry coalition that includes the entire payer lobby and the entire hospital lobby’s investment arms, and a federalism argument that corporate practice doctrine has been state licensure law since the 1930s and should stay there. That last argument is not frivolous. A federal statute regulating who may own a professional corporation formed under state law, enforced partly through state attorneys general, is a novel construction that would get litigated for years even if it passed.
Probability that the substance arrives anyway: very high, and largely already underway. Somewhere north of 15 states now require pre-close transaction notice. California, Oregon, Indiana, Massachusetts, New Mexico, Connecticut, Colorado, Illinois, Rhode Island, Vermont, Washington, Maine, and Delaware have all moved in some form. Pennsylvania’s bill passed the House and got narrowed in the Senate. More than 20 additional bills are pending. The federal bill’s real function is to supply model language, political cover, and a national frame to state legislators who were going to introduce something in January anyway. Warren does not need to pass it. She needs 20 statehouses to copy it.
Three things worth watching, in order of signal value.
First, the January 1, 2029 Oregon cliff and the sell-side behavior that precedes it. If Oregon platforms restructure quietly and keep operating, the compliance cost is absorbable and the model survives in modified form. If they sell to hospital systems or exit the state, that is evidence the reform is a prohibition in practice, and it is also the clearest natural experiment anyone will get on whether corporate practice enforcement raises or lowers prices.
Second, whether any state enacts a private right of action with multiplied damages. The federal bill includes it. The state bills mostly do not yet. That single provision does more to change behavior than every ownership restriction combined, because it converts enforcement from a budget question into a market. Rhode Island’s pending language and Connecticut’s proposals are the ones to read closely.
Third, whether the telehealth carve-out replicates. Oregon exempted practices with no physical location in the state. If that language travels into other statutes and into any eventual federal text, the practical effect of the corporate practice revival is to tax physical clinical infrastructure and subsidize virtual care delivered by the exact same structures. That would be a strange outcome for a movement that started with people being angry about a hospital in Massachusetts closing.
The broader read is that the era of buying physician practices as a financial engineering exercise is ending for ordinary reasons, and the legislation is arriving after the fact to take credit. Deal count was already down by half. The installed base already stopped growing. Multiples already compressed three turns. Congress showing up in September 2026 to ban a strategy that the capital markets already deprecated is a familiar pattern in this industry, and it usually means the next thing is already being built somewhere, under a structure nobody has written a law about yet. Probably with an MSO in it
.